Drug class
Antineoplastic tropomyosin receptor kinase (TRK) inhibitors are a targeted therapeutic class of small-molecule kinase inhibitors designed to block the activity of TRK proteins encoded by the neurotrophic receptor tyrosine kinase genes (*NTRK1*, *NTRK2*, and *NTRK3*). Read more about Antineoplastic - Tropomyosin Receptor Kinase (TRK) Inhibitor
1 drugs in this class 1 manufacturers
Antineoplastic tropomyosin receptor kinase (TRK) inhibitors are a targeted therapeutic class of small-molecule kinase inhibitors designed to block the activity of TRK proteins encoded by the neurotrophic receptor tyrosine kinase genes (*NTRK1*, *NTRK2*, and *NTRK3*).
By binding to the catalytic domain of these receptor tyrosine kinases, they inhibit downstream oncogenic signaling cascades—such as the MAPK and PI3K/AKT pathways—that drive uncontrolled cell proliferation, survival, and metastasis.
These agents serve as tumor-agnostic therapies indicated for adult and pediatric advanced solid tumors harboring oncogenic *NTRK* gene fusions, which occur across diverse malignancies including infantile fibrosarcoma, secretory breast carcinoma, salivary gland tumors, thyroid carcinomas, lung cancers, and colorectal cancers.
Antineoplastic tropomyosin receptor kinase (TRK) inhibitors are a targeted therapeutic class of small-molecule kinase inhibitors designed to block the activity of TRK proteins encoded by the neurotrophic receptor tyrosine kinase genes (*NTRK1*, *NTRK2*, and *NTRK3*) These agents serve as tumor-agnostic therapies indicated for adult and pediatric advanced solid tumors harboring oncogenic *NTRK* gene fusions, which occur across diverse malignancies including infantile fibrosarcoma, secretory breas...
Antineoplastic tropomyosin receptor kinase (TRK) inhibitors are a targeted therapeutic class of small-molecule kinase inhibitors designed to block the activity of TRK proteins encoded by the neurotrophic receptor tyrosine kinase genes (*NTRK1*, *NTRK2*, and *NTRK3*) By binding to the catalytic domain of these receptor tyrosine kinases, they inhibit downstream oncogenic signaling cascades—such as the MAPK and PI3K/AKT pathways—that drive uncontrolled cell proliferation, survival, and metastasis
By binding to the catalytic domain of these receptor tyrosine kinases, they inhibit downstream oncogenic signaling cascades—such as the MAPK and PI3K/AKT pathways—that drive uncontrolled cell proliferation, survival, and metastasis
These agents serve as tumor-agnostic therapies indicated for adult and pediatric advanced solid tumors harboring oncogenic *NTRK* gene fusions, which occur across diverse malignancies including infantile fibrosarcoma, secretory breast carcinoma, salivary gland tumors, thyroid carcinomas, lung cancers, and colorectal cancers
These agents serve as tumor-agnostic therapies indicated for adult and pediatric advanced solid tumors harboring oncogenic *NTRK* gene fusions, which occur across diverse malignancies including infantile fibrosarcoma, secretory breast carcinoma, salivary gland tumors, thyroid carcinomas, lung cancers, and colorectal cancers
These agents serve as tumor-agnostic therapies indicated for adult and pediatric advanced solid tumors harboring oncogenic *NTRK* gene fusions, which occur across diverse malignancies including infantile fibrosarcoma, secretory breast carcinoma, salivary gland tumors, thyroid carcinomas, lung cancers, and colorectal cancers
Following a drug class requires a free Physicians Office Resource account.
